A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
Clinical trial NCT05853432 · COMPLETED
Trial details
- NCT number
- NCT05853432
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-03-16
- Primary completion
- 2022-05-02
- Enrollment
- 157
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.